Serum and cytoplasmic IFN-γ increase following administration of α-GalCer–pulsed MoDCs. (A) Serum IFN-γ levels following therapy with α-GalCer–pulsed MoDCs in 4 representative cases. (B-C) The percentage (B) and total number (C) of PB NK cells and T cells expressing cytoplasmic IFN-γ, indicating the time course of in vivo activation of NK cells and T cells following therapy with α-GalCer–pulsed MoDCs in one representative patient (KS202). Empty circles (○) indicate administration of α-GalCer–pulsed MoDCs.